Literature DB >> 21837342

Library of second-generation cycloruthenated compounds and evaluation of their biological properties as potential anticancer drugs: passing the nanomolar barrier.

Ludivine Fetzer1, Bastien Boff, Moussa Ali, Meng Xiangjun, Jean-Paul Collin, Claude Sirlin, Christian Gaiddon, Michel Pfeffer.   

Abstract

A library of 32 organoruthenium compounds has been synthesised. Known and novel C-N cyclometalated compounds as well as N-C-N and N-N-C pincer derivatives of this metal have been used in this purpose. Most of the compounds have been tested for their in vitro antitumoral behaviours, good to excellent activities have thus been found. Several of the newly synthesized compounds pass the symbolic barrier of the nanomolar range for their IC(50) indicating a critical improvement. The level of activity is tentatively correlated to physicochemical properties of the compounds such as their Ru(III/II) redox potential and their lipophilicity (log P). This journal is © The Royal Society of Chemistry 2011

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21837342     DOI: 10.1039/c1dt10322a

Source DB:  PubMed          Journal:  Dalton Trans        ISSN: 1477-9226            Impact factor:   4.390


  13 in total

1.  Cyclometalated Ruthenium(II) Complexes Derived from α-Oligothiophenes as Highly Selective Cytotoxic or Photocytotoxic Agents.

Authors:  Goutam Ghosh; Katsuya L Colón; Anderson Fuller; Tariq Sainuddin; Evan Bradner; Julia McCain; Susan M A Monro; Huimin Yin; Marc W Hetu; Colin G Cameron; Sherri A McFarland
Journal:  Inorg Chem       Date:  2018-06-21       Impact factor: 5.165

2.  UV-vis absorption spectrum of a novel Ru(II) complex intercalated in DNA: [Ru(2,2'-bipy)(dppz)(2,2'-ArPy)]⁺.

Authors:  Agisilaos Chantzis; Thibaut Very; Stéphane Despax; Jean-Thomas Issenhuth; Alex Boeglin; Pascal Hébraud; Michel Pfeffer; Antonio Monari; Xavier Assfeld
Journal:  J Mol Model       Date:  2014-02-22       Impact factor: 1.810

3.  Impact of aromaticity on anticancer activity of polypyridyl ruthenium(II) complexes: synthesis, structure, DNA/protein binding, lipophilicity and anticancer activity.

Authors:  Petar Čanović; Ana Rilak Simović; Snežana Radisavljević; Ioannis Bratsos; Nicola Demitri; Marina Mitrović; Ivanka Zelen; Živadin D Bugarčić
Journal:  J Biol Inorg Chem       Date:  2017-07-10       Impact factor: 3.358

4.  Highly cytotoxic trithiophenolatodiruthenium complexes of the type [(η6-p-MeC6H4Pri)2Ru2(SC6H4-p-X)3]+: synthesis, molecular structure, electrochemistry, cytotoxicity, and glutathione oxidation potential.

Authors:  Federico Giannini; Julien Furrer; Anne-Flore Ibao; Georg Süss-Fink; Bruno Therrien; Olivier Zava; Mathurin Baquie; Paul J Dyson; Petr Stěpnička
Journal:  J Biol Inorg Chem       Date:  2012-06-16       Impact factor: 3.358

5.  2-Phenylpyridine ruthenacycles as effectors of glucose oxidase activity: inhibition by Ru(II) and activation by Ru(III).

Authors:  Rafael Omar Saavedra Díaz; Ronan Le Lagadec; Alexander D Ryabov
Journal:  J Biol Inorg Chem       Date:  2013-04-27       Impact factor: 3.358

Review 6.  The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials.

Authors:  Leli Zeng; Pranav Gupta; Yanglu Chen; Enju Wang; Liangnian Ji; Hui Chao; Zhe-Sheng Chen
Journal:  Chem Soc Rev       Date:  2017-10-02       Impact factor: 54.564

7.  Photodissociation of a ruthenium(II) arene complex and its subsequent interactions with biomolecules: a density functional theory study.

Authors:  Hanlu Wang; Nathan J DeYonker; Xiting Zhang; Cunyuan Zhao; Liangnian Ji; Zong-Wan Mao
Journal:  J Mol Model       Date:  2012-06-01       Impact factor: 1.810

8.  Synthesis, substitution kinetics, DNA/BSA binding and cytotoxicity of tridentate N^E^N (E = NH, O, S) pyrazolyl palladium(II) complexes.

Authors:  Reinner O Omondi; Adewale O Fadaka; Amos A Fatokun; Deogratius Jaganyi; Stephen O Ojwach
Journal:  J Biol Inorg Chem       Date:  2022-10-05       Impact factor: 3.862

9.  A ruthenium anticancer compound interacts with histones and impacts differently on epigenetic and death pathways compared to cisplatin.

Authors:  Cynthia Licona; Marie-Elodie Spaety; Antonelle Capuozzo; Moussa Ali; Rita Santamaria; Olivier Armant; Francois Delalande; Alain Van Dorsselaer; Sarah Cianferani; John Spencer; Michel Pfeffer; Georg Mellitzer; Christian Gaiddon
Journal:  Oncotarget       Date:  2017-01-10

10.  Ruthenium(II) Complexes with 2-Phenylimidazo[4,5-f][1,10]phenanthroline Derivatives that Strongly Combat Cisplatin-Resistant Tumor Cells.

Authors:  Leli Zeng; Yu Chen; Jiangping Liu; Huaiyi Huang; Ruilin Guan; Liangnian Ji; Hui Chao
Journal:  Sci Rep       Date:  2016-01-14       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.